Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Front Immunol. 2019 May 29;10:821. doi: 10.3389/fimmu.2019.00821. eCollection 2019.
Mast cells and their mediators have been implicated in the pathogenesis of asthma and allergy for decades. Allergic asthma is a complex chronic lung disease in which several different immune cells, genetic factors and environmental exposures influence the pathology. Mast cells are key players in the asthmatic response through secretion of a multitude of mediators with pro-inflammatory and airway-constrictive effects. Well-known mast cell mediators, such as histamine and bioactive lipids are responsible for many of the physiological effects observed in the acute phase of allergic reactions. The accumulation of mast cells at particular sites of the allergic lung is likely relevant to the asthma phenotype, severity and progression. Mast cells located in different compartments in the lung and airways have different characteristics and express different mediators. According to experiments in mice, lung mast cells develop from mast cell progenitors induced by inflammatory stimuli to migrate to the airways. Human mast cell progenitors have been identified in the blood circulation. A high frequency of circulating human mast cell progenitors may reflect ongoing pathological changes in the allergic lung. In allergic asthma, mast cells become activated mainly via IgE-mediated crosslinking of the high affinity receptor for IgE (FcεRI) with allergens. However, mast cells can also be activated by numerous other stimuli e.g. toll-like receptors and MAS-related G protein-coupled receptor X2. In this review, we summarize research with implications on the role and development of mast cells and their progenitors in allergic asthma and cover selected activation pathways and mast cell mediators that have been implicated in the pathogenesis. The review places an emphasis on describing mechanisms identified using mouse models and data obtained by analysis of clinical samples.
几十年来,肥大细胞及其介质一直被认为与哮喘和过敏的发病机制有关。过敏性哮喘是一种复杂的慢性肺部疾病,其中几种不同的免疫细胞、遗传因素和环境暴露影响着病理学。肥大细胞是哮喘反应中的关键参与者,通过分泌具有促炎和气道收缩作用的多种介质发挥作用。众所周知的肥大细胞介质,如组胺和生物活性脂质,是许多在过敏反应急性期观察到的生理效应的原因。肥大细胞在过敏肺部的特定部位积聚可能与哮喘表型、严重程度和进展有关。位于肺部和气道不同部位的肥大细胞具有不同的特征,并表达不同的介质。根据小鼠实验,肺部肥大细胞由炎症刺激诱导的肥大细胞祖细胞发育而来,然后迁移到气道。已经在血液循环中鉴定出人类肥大细胞祖细胞。循环中人类肥大细胞祖细胞的高频率可能反映了过敏肺部持续存在的病理变化。在过敏性哮喘中,肥大细胞主要通过 IgE 介导的高亲和力 IgE 受体(FcεRI)与过敏原交联而被激活。然而,肥大细胞也可以被许多其他刺激物激活,例如 Toll 样受体和 MAS 相关 G 蛋白偶联受体 X2。在这篇综述中,我们总结了与肥大细胞及其祖细胞在过敏性哮喘中的作用和发展相关的研究,并涵盖了已被认为与发病机制有关的选定激活途径和肥大细胞介质。这篇综述重点描述了使用小鼠模型确定的机制以及通过分析临床样本获得的数据。